Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada

BMC Psychiatry

Table 1 Model inputs: clinical parameters

	Base-case		Lower bound		Upper bound
Target population[16]–[19]
Age at onset	40		20		N/A
Incidence of adverse effects[18]
Significant weight gain
Asenapine	39.2%		29.4%		49.0%
Olanzapine	55.1%		41.3%		68.9%
EPS-related event
Asenapine	10.7%		7.2%		14.9%
Olanzapine	9.5%		6.8%		13.1%
Risks of developing complications (OR)
	Men	Women	Men	Women	Men	Women
Diabetes [21, 22]	2.69	1.9	2.17	1.5	3.34	2.3
Hypertension [23, 24]	1.68	1.56	1.45	1.48	1.94	1.64
CHDs [22, 25]	1.68	1.25	1.13	1.01	2.5	1.55
Stroke [26]	1.02	1.02	1.01	1.01	1.03	1.03
Mortality risks	Men	Women	Men	Women	Men	Women
Diabetes [27]	1.88	1.88	1.55	1.55	2.27	2.27
Hypertension [28]	1.44	1.34	1.00	1.00	2.88	2.68
CHDs [29, 30]	2.20	1.60	2.00	1.20	2.40	2.10
Stroke [31]	2.37	2.37	2.11	2.07	2.64	2.70
Utilities/Disutilities
Disease-related[32]
BPD	0.800		0.580		1.000
Weight gain in BPD	-0.066		-0.050		-0.083
EPS in BPD	-0.074		-0.090		-0.053
Weight of additional disutilities	0		0.5		1.0
Complications[33]	Men	Women	Men	Women	Men	Women
Type II diabetes	-0.06	-0.05	-0.08	-0.08	-0.03	-0.03
Hypertension	-0.02	0	-0.03	-0.02	0	0.01
CHDs (Heart disease)	-0.07	-0.06	-0.09	-0.08	-0.05	-0.03
Effects of stroke	-0.17	-0.18	-0.23	-0.25	-0.12	-0.10
Suicide rate[34]	15.50		12.25		18.44

ISSN: 1471-244X